Roche’s Q1 2016 Earnings Support Our Bullish Stance
Key Takeaways From Roche’s Q1 2016 Earnings
- Cancer Behemoths Avastin, Herceptin & Rituxan Are Still Growing
- New Cancer Drugs Have Significant Growth Potential
- Drug Pipeline Is Looking Interesting
- Overall, Earnings Results Re-Affirm Our Bullish Stance On Roche
Have more questions about Roche? See the links below.
- Roche’s Stock May Have Been Down, But The Company’s Business Has Strong Outlook
- What Drove 15% Growth in Roche’s Earnings Between 2011-2014 Even Though Other Big Pharma Companies Suffered A Decline?
- Why Is Market Assigning Low Earnings Multiple To Roche Despite Its Biotech Focus?
- Can Roche Grow Its Earnings By 15% In The Next 3 Years?
- With Biosimilars Getting Approval In Europe, Does Roche’s 2016 EPS Face A Meaningful Risk?
- How Can Roche Get 25% Boost In Revenues In 5 Years?
- Can Emerging Biosimilar Competition Cause > 10% Downside To Roche’s Valuation?
- Here Is Why We Are Bullish On Roche
- Three Things To Watch Out For Roche This Year
Notes:
See More at Trefis | View Interactive Institutional Research (Powered by Trefis)